/ 2 items

#RPRX↓

RPRX/ 12/29/2025 · 5:09 PM

Royalty Pharma Completes $240M Deal for Full Evrysdi Royalty Rights

Royalty Pharma acquires complete royalty interest in Roche's Evrysdi for $240M upfront plus milestones, consolidating ownership of the 8-16% tiered royalty stream.

DNLI/ 12/04/2025 · 12:30 PM

Denali and Royalty Pharma Strike $275M Deal for Hunter Syndrome Treatment

Denali Therapeutics secures $275 million from Royalty Pharma for tividenofusp alfa, a promising therapy for Hunter syndrome awaiting FDA approval in April 2026.